Literature DB >> 17241126

Myelin-associated glycoprotein (MAG): past, present and beyond.

Richard H Quarles1.   

Abstract

The myelin-associated glycoprotein (MAG) is a type I transmembrane glycoprotein localized in periaxonal Schwann cell and oligodendroglial membranes of myelin sheaths where it functions in glia-axon interactions. It contains five immunoglobulin (Ig)-like domains and is in the sialic acid-binding subgroup of the Ig superfamily. It appears to function both as a ligand for an axonal receptor that is needed for the maintenance of myelinated axons and as a receptor for an axonal signal that promotes the differentiation, maintenance and survival of oligodendrocytes. Its function in the maintenance of myelinated axons may be related to its role as one of the white matter inhibitors of neurite outgrowth acting through a receptor complex involving the Nogo receptor and/or gangliosides containing 2,3-linked sialic acid. MAG is expressed as two developmentally regulated isoforms with different cytoplasmic domains that may activate different signal transduction pathways in myelin-forming cells. MAG contains a carbohydrate epitope shared with other glycoconjugates that is a target antigen in autoimmune peripheral neuropathy associated with IgM gammopathy and has been implicated in a dying back oligodendrogliopathy in multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17241126     DOI: 10.1111/j.1471-4159.2006.04319.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  111 in total

1.  Myelin-associated glycoprotein (MAG) protects neurons from acute toxicity using a ganglioside-dependent mechanism.

Authors:  Niraj R Mehta; Thien Nguyen; John W Bullen; John W Griffin; Ronald L Schnaar
Journal:  ACS Chem Neurosci       Date:  2010-03-17       Impact factor: 4.418

Review 2.  Myelination and support of axonal integrity by glia.

Authors:  Klaus-Armin Nave
Journal:  Nature       Date:  2010-11-11       Impact factor: 49.962

3.  Deletion of 19q13 reveals clinical overlap with Dubowitz syndrome.

Authors:  Jill E Urquhart; Simon G Williams; Sanjeev S Bhaskar; Naomi Bowers; Jill Clayton-Smith; William G Newman
Journal:  J Hum Genet       Date:  2015-09-17       Impact factor: 3.172

Review 4.  Basic and clinical immunology of Siglecs.

Authors:  Stephan von Gunten; Bruce S Bochner
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

5.  Sumoylated HSP90 is a dominantly inherited plasma cell dyscrasias risk factor.

Authors:  Klaus-Dieter Preuss; Michael Pfreundschuh; Martin Weigert; Natalie Fadle; Evi Regitz; Boris Kubuschok
Journal:  J Clin Invest       Date:  2014-12-08       Impact factor: 14.808

6.  Developmental changes in plasticity, synaptic, glia and connectivity protein levels in rat dorsal hippocampus.

Authors:  Alessio Travaglia; Reto Bisaz; Emmanuel Cruz; Cristina M Alberini
Journal:  Neurobiol Learn Mem       Date:  2016-08-12       Impact factor: 2.877

Review 7.  Usher syndrome: Hearing loss, retinal degeneration and associated abnormalities.

Authors:  Pranav Mathur; Jun Yang
Journal:  Biochim Biophys Acta       Date:  2014-12-04

8.  Myelin protein zero is naturally processed in the B cells of monoclonal gammopathy of undetermined significance of immunoglobulin M isotype: aberrant triggering of a patient's T cells.

Authors:  Eva Hellqvist; Maria Kvarnström; Anita Söderberg; Magnus Vrethem; Jan Ernerudh; Anders Rosén
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

9.  Myelin-associated glycoprotein mediates membrane fusion and entry of neurotropic herpesviruses.

Authors:  Tadahiro Suenaga; Takeshi Satoh; Pranee Somboonthum; Yasushi Kawaguchi; Yasuko Mori; Hisashi Arase
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

Review 10.  Sweet complementarity: the functional pairing of glycans with lectins.

Authors:  H-J Gabius; J C Manning; J Kopitz; S André; H Kaltner
Journal:  Cell Mol Life Sci       Date:  2016-03-08       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.